Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE
PACTR202102669041711Phase 3Not yet recruiting
- Sponsor
- Global Blood Therapeutics
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Voxelotor + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Resolution of target ulcer(s) by Week 12. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202102669041711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102669041711.